Health
Anvisa authorizes human trials of Brazilian malaria vaccine
The initial phase will assess safety and immune response in 48 volunteers aged 18 to 59, with follow-up expected for 360 days.
You have used your 3 free reads for today
The full text of this story becomes available after the daily renewal. Sports and entertainment stay open. The paid subscription is not open yet.
Your free reads renew on 11/15/2026 at 00:00 (Brasília time).
The essentials of this story
- What happened
- Anvisa authorized the start of human trials of the Brazilian vaccine Vivaxin against vivax malaria.
- Who is affected
- The research involves 48 volunteers aged 18 to 59 and is mainly aimed at preventing the disease in Brazil.
- What changes
- Phase 1 will test safety and immune response over 360 days, with R$ 12 million planned for the next clinical stages.
Create a free account to keep reading: 3 full stories a day.
The paid subscription is not on sale yet. Free sign-up already works. Planned monthly price: R$ 9.90 (in US dollars and euros, a direct conversion at the official rate on the day you subscribe).
Sources
- Malária: Anvisa autoriza teste em humanos de vacina 100% brasileira — Agência Brasil — saúde
- Anvisa autoriza teste em humanos de vacina brasileira para malária — Poder360
- Anvisa libera testes em humanos de vacina brasileira contra malária — Folha de S.Paulo — em cima da hora